AU2014362231B2 - Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology - Google Patents

Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology Download PDF

Info

Publication number
AU2014362231B2
AU2014362231B2 AU2014362231A AU2014362231A AU2014362231B2 AU 2014362231 B2 AU2014362231 B2 AU 2014362231B2 AU 2014362231 A AU2014362231 A AU 2014362231A AU 2014362231 A AU2014362231 A AU 2014362231A AU 2014362231 B2 AU2014362231 B2 AU 2014362231B2
Authority
AU
Australia
Prior art keywords
methyl
amino
pyrimidin
carboxamide
tert
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014362231A
Other languages
English (en)
Other versions
AU2014362231A1 (en
Inventor
Timothy Raymond CHAN
Brian T. Hopkins
Kevin Koch
Gnanasambandam Kumaravel
Joseph P. Lyssikatos
Bin Ma
Hua Miao
Lihong Sun
Lei Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Publication of AU2014362231A1 publication Critical patent/AU2014362231A1/en
Assigned to BIOGEN MA INC. reassignment BIOGEN MA INC. Amend patent request/document other than specification (104) Assignors: BIOGEN MA INC., SUNESIS PHARMACEUTICALS, INC.
Priority to AU2019201997A priority Critical patent/AU2019201997C1/en
Application granted granted Critical
Publication of AU2014362231B2 publication Critical patent/AU2014362231B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU2014362231A 2013-12-11 2014-12-11 Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology Active AU2014362231B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2019201997A AU2019201997C1 (en) 2013-12-11 2019-03-22 Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361914886P 2013-12-11 2013-12-11
US61/914,886 2013-12-11
PCT/US2014/069853 WO2015089337A1 (en) 2013-12-11 2014-12-11 Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019201997A Division AU2019201997C1 (en) 2013-12-11 2019-03-22 Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology

Publications (2)

Publication Number Publication Date
AU2014362231A1 AU2014362231A1 (en) 2016-07-07
AU2014362231B2 true AU2014362231B2 (en) 2019-04-04

Family

ID=52302344

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014362231A Active AU2014362231B2 (en) 2013-12-11 2014-12-11 Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
AU2019201997A Active AU2019201997C1 (en) 2013-12-11 2019-03-22 Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2019201997A Active AU2019201997C1 (en) 2013-12-11 2019-03-22 Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology

Country Status (32)

Country Link
US (4) US9809577B2 (https=)
EP (3) EP3357921A3 (https=)
JP (4) JP6431914B2 (https=)
KR (1) KR102413253B1 (https=)
CN (3) CN108947913A (https=)
AR (2) AR098721A1 (https=)
AU (2) AU2014362231B2 (https=)
BR (1) BR112016012860A2 (https=)
CA (1) CA2932608C (https=)
CL (2) CL2016001435A1 (https=)
CY (1) CY1120517T1 (https=)
DK (1) DK3080103T3 (https=)
EA (2) EA037942B1 (https=)
ES (1) ES2678021T3 (https=)
HR (1) HRP20181109T1 (https=)
HU (1) HUE040346T2 (https=)
IL (2) IL246031B (https=)
LT (1) LT3080103T (https=)
MX (2) MX370103B (https=)
MY (1) MY179781A (https=)
NZ (1) NZ721217A (https=)
PH (1) PH12016501107B1 (https=)
PL (1) PL3080103T3 (https=)
PT (1) PT3080103T (https=)
RS (1) RS57662B1 (https=)
SA (1) SA518391170B1 (https=)
SG (2) SG11201604595VA (https=)
SI (1) SI3080103T1 (https=)
SM (1) SMT201800373T1 (https=)
TW (3) TWI608002B (https=)
WO (1) WO2015089337A1 (https=)
ZA (1) ZA201706244B (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ598985A (en) * 2009-09-04 2013-07-26 Biogen Idec Inc Bruton's tyrosine kinase inhibitors
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
AU2014362231B2 (en) 2013-12-11 2019-04-04 Biogen Ma Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
CA2988576A1 (en) * 2015-06-10 2016-12-15 Biogen Ma Inc. Adipate forms and compositions of biaryl inhibitors of bruton's tyrosine kinase
US20180282310A1 (en) 2015-06-10 2018-10-04 Biogen Ma Inc. Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase
EP3388428B1 (en) * 2015-12-07 2021-08-04 Suzhou Sinovent Pharmaceuticals Company Five-membered heterocyclic amides wnt pathway inhibitor
JO3793B1 (ar) * 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
JO3794B1 (ar) * 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
KR20190006952A (ko) * 2016-03-31 2019-01-21 라이언 티씨알 피티이. 리미티드 외인성 바이러스-특이적 t 세포 수용체 (tcr)를 발현하는 비-활성화된 t 세포
US10710993B2 (en) 2016-06-27 2020-07-14 Hangzhou REX Pharmaceutical Co., LTD. Benzofuran pyrazole amine kinase inhibitor
JP7214632B2 (ja) 2016-07-21 2023-01-30 バイオジェン エムエー インク． ブルトン型チロシンキナーゼ阻害剤のコハク酸塩形態および組成物
WO2018124001A1 (ja) 2016-12-27 2018-07-05 国立研究開発法人理化学研究所 Ｂｍｐシグナル阻害化合物
IL269933B (en) * 2017-04-14 2022-07-01 Biogen Ma Inc Benzozapine analogues as inhibitors for proton tyrosine kinase
EP3737677B1 (en) 2018-01-10 2021-11-03 Allinky Biopharma Tetrahydroisoquinoline compounds
WO2019144041A1 (en) 2018-01-19 2019-07-25 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
US20190330226A1 (en) * 2018-04-26 2019-10-31 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
EP3793994B1 (en) 2018-05-14 2023-08-23 Biogen MA Inc. Inhibiting agents for bruton's tyrosine kinase
JP7610985B2 (ja) 2018-06-26 2025-01-09 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
CN117285467A (zh) 2018-07-31 2023-12-26 罗索肿瘤学公司 喷雾干燥的分散体和制剂
US11820760B2 (en) 2018-10-15 2023-11-21 Biogen Ma Inc. Crystalline polymorphs of Bruton's tyrosine kinase inhibitors
WO2020118683A1 (en) * 2018-12-14 2020-06-18 Lynk Pharmaceuticals Co. Ltd. Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
US12240838B2 (en) 2019-05-15 2025-03-04 Biogen Ma Inc. Inhibiting agents for Bruton's tyrosine kinase
CN110627775B (zh) * 2019-10-24 2026-01-30 特科罗生物科技(成都)有限公司 一种小分子化合物
EP4081514A1 (en) * 2019-12-23 2022-11-02 Biogen MA Inc. Btk inhibitors
CN116917279A (zh) * 2020-08-07 2023-10-20 渤健马萨诸塞州股份有限公司 Btk抑制剂
TW202220972A (zh) * 2020-08-07 2022-06-01 美商百健Ｍａ公司 Ｂｔｋ抑制劑
EP4313023A1 (en) 2021-04-02 2024-02-07 Biogen MA Inc. Combination treatment methods of multiple sclerosis
JP2024525181A (ja) * 2021-06-21 2024-07-10 ベイジーン スウィッツァーランド ゲーエムベーハー （ｒ）－グルタルイミドｃｒｂｎリガンド及び使用方法
KR20240128831A (ko) 2021-12-30 2024-08-27 베이진 스위찰랜드 게엠베하 브루톤 티로신 키나아제(btk) 억제제와 e3 리가아제 리간드의 접합에 의한 btk의 분해 및 사용 방법
CN116891437B (zh) * 2022-04-06 2025-10-28 长春金赛药业有限责任公司 氨基酸衍生物、药物组合物及其制备方法和应用
WO2024146923A1 (en) 2023-01-04 2024-07-11 Ab Science Tubulin polymerization inhibitors
CN117088851A (zh) * 2023-07-13 2023-11-21 特科罗生物科技(成都)有限公司 一种嘧啶胺类nuak抑制剂及其制备方法和用途
WO2026012424A1 (zh) * 2024-07-10 2026-01-15 江苏恒瑞医药股份有限公司 一种杂芳基类化合物、其制备方法及其在医药上的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008116064A2 (en) * 2007-03-21 2008-09-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
WO2009045175A1 (en) * 2007-10-05 2009-04-09 S*Bio Pte Ltd Pyrimidine substituted purine derivatives
US8334292B1 (en) * 2010-06-14 2012-12-18 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US833429A (en) * 1902-07-31 1906-10-16 Anthony Van Wagenen Automatic system of intercommunication.
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
GB9924862D0 (en) * 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
WO2002012198A2 (en) * 2000-08-08 2002-02-14 Ortho-Mcneil Pharmaceutical, Inc. 4-pyrimidinamine derivatives, pharmaceutical compositions and related methods
US20050014753A1 (en) 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
GB0325031D0 (en) * 2003-10-27 2003-12-03 Novartis Ag Organic compounds
US20080275062A1 (en) * 2004-01-30 2008-11-06 David Harold Drewry Chemical Compounds
US20060178388A1 (en) * 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
UA109411C2 (uk) * 2005-11-01 2015-08-25 N-трет-бутил-3-(2-хлор-5-метилпіримідин-4-іламіно)бензолсульфонамід та його застосування в способі одержання сполуки
JP5191391B2 (ja) * 2005-11-01 2013-05-08 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤
KR20080110998A (ko) * 2006-01-30 2008-12-22 엑셀리시스, 인코포레이티드 Ｊａｋ­２ 조절자로서 ４­아릴­２­아미노­피리미딘 또는 4­아릴­２­아미노알킬­피리미딘 및 이들을 포함하는 약제학적 조성물
AR063946A1 (es) * 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
WO2008053182A1 (en) * 2006-11-01 2008-05-08 Chroma Therapeutics Ltd. IKK-β SERINE-THREONINE PROTEIN KINASE INHIBITORS
US20120101114A1 (en) * 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
AR074199A1 (es) * 2008-11-20 2010-12-29 Glaxosmithkline Llc Compuesto de 6-(4-pirimidinil)-1h-indazol, composiciones farmaceuticas que lo comprenden y su uso para preparar un medicamento util para el tratamiento o disminucion de la gravedad del cancer.
EP2485589A4 (en) * 2009-09-04 2013-02-06 Biogen Idec Inc HETEROARYL-BTK INHIBITORS
NZ598985A (en) * 2009-09-04 2013-07-26 Biogen Idec Inc Bruton's tyrosine kinase inhibitors
JP2014500254A (ja) 2010-11-09 2014-01-09 セルゾーム リミティッド Ｔｙｋ２阻害剤としてのピリジン化合物およびそのアザ類似体
WO2012133310A1 (ja) 2011-03-31 2012-10-04 美津濃株式会社 アイアンゴルフクラブヘッドおよびアイアンゴルフクラブ
MX2013011908A (es) 2011-04-12 2014-03-27 Alzheimer S Inst Of America Inc Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
AR091273A1 (es) * 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
AU2014362231B2 (en) 2013-12-11 2019-04-04 Biogen Ma Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
EP3444251B1 (en) 2013-12-11 2023-06-07 Biogen MA Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
US10064869B2 (en) * 2014-06-04 2018-09-04 Thomas Helledays Stiftelse For Medicinsk Forskning MTH1 inhibitors for treatment of inflammatory and autoimmune conditions
US10253023B2 (en) * 2014-10-06 2019-04-09 Merck Patent Gmbh Heteroaryl compounds as BTK inhibitors and uses thereof
US20180282310A1 (en) 2015-06-10 2018-10-04 Biogen Ma Inc. Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase
IL269933B (en) 2017-04-14 2022-07-01 Biogen Ma Inc Benzozapine analogues as inhibitors for proton tyrosine kinase

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008116064A2 (en) * 2007-03-21 2008-09-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
WO2009045175A1 (en) * 2007-10-05 2009-04-09 S*Bio Pte Ltd Pyrimidine substituted purine derivatives
US8334292B1 (en) * 2010-06-14 2012-12-18 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same

Also Published As

Publication number Publication date
SMT201800373T1 (it) 2018-09-13
WO2015089337A1 (en) 2015-06-18
EA030538B1 (ru) 2018-08-31
SG10201908558WA (en) 2019-10-30
RS57662B1 (sr) 2018-11-30
CL2016001435A1 (es) 2017-06-09
HRP20181109T1 (hr) 2018-11-02
IL269569B (en) 2021-03-25
EA201691114A1 (ru) 2016-11-30
US20160311802A1 (en) 2016-10-27
MX2016007611A (es) 2016-09-09
CN108947913A (zh) 2018-12-07
HUE040346T2 (hu) 2019-03-28
SG11201604595VA (en) 2016-07-28
TWI744672B (zh) 2021-11-01
ZA201706244B (en) 2019-04-24
EP3080103B1 (en) 2018-04-18
AU2019201997A1 (en) 2019-04-18
TW201536765A (zh) 2015-10-01
AR110381A2 (es) 2019-03-20
US11572356B2 (en) 2023-02-07
US20190218204A1 (en) 2019-07-18
JP7076022B2 (ja) 2022-05-26
LT3080103T (lt) 2018-08-10
AU2014362231A1 (en) 2016-07-07
US20180093973A1 (en) 2018-04-05
IL246031A0 (en) 2016-08-02
CN109096274B (zh) 2022-07-01
PT3080103T (pt) 2018-07-23
MX370103B (es) 2019-12-02
MY179781A (en) 2020-11-13
CA2932608C (en) 2023-02-14
EA201792348A1 (ru) 2018-09-28
JP2016539996A (ja) 2016-12-22
CN106459002B (zh) 2018-08-21
KR20160106072A (ko) 2016-09-09
MX2019014228A (es) 2020-01-23
BR112016012860A2 (pt) 2017-08-08
TWI608002B (zh) 2017-12-11
SI3080103T1 (sl) 2018-11-30
JP2019163280A (ja) 2019-09-26
EP3080103A1 (en) 2016-10-19
US10759783B2 (en) 2020-09-01
TWI675833B (zh) 2019-11-01
NZ721217A (en) 2021-12-24
TW202017931A (zh) 2020-05-16
AU2019201997B2 (en) 2020-09-17
JP6431914B2 (ja) 2018-11-28
EP3357921A3 (en) 2018-09-12
EP3357921A2 (en) 2018-08-08
JP2018035201A (ja) 2018-03-08
IL246031B (en) 2019-10-31
JP6526167B2 (ja) 2019-06-05
CL2017001459A1 (es) 2018-03-23
CN109096274A (zh) 2018-12-28
CN106459002A (zh) 2017-02-22
SA518391170B1 (ar) 2022-08-25
EA037942B1 (ru) 2021-06-10
DK3080103T3 (en) 2018-07-30
TW201811772A (zh) 2018-04-01
US9809577B2 (en) 2017-11-07
AR098721A1 (es) 2016-06-08
PL3080103T3 (pl) 2018-10-31
EP3872075A1 (en) 2021-09-01
AU2019201997C1 (en) 2021-03-18
PH12016501107B1 (en) 2021-07-21
US10081619B2 (en) 2018-09-25
US20220332705A1 (en) 2022-10-20
EP3080103B9 (en) 2018-09-19
JP2021091733A (ja) 2021-06-17
CA2932608A1 (en) 2015-06-18
KR102413253B1 (ko) 2022-06-27
MX388978B (es) 2025-03-20
ES2678021T3 (es) 2018-08-08
PH12016501107A1 (en) 2016-07-11
IL269569A (en) 2019-11-28
CY1120517T1 (el) 2019-07-10

Similar Documents

Publication Publication Date Title
AU2014362231B2 (en) Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
JP7216705B2 (ja) Ｔｙｋ２阻害剤およびその使用方法
EP3152210B1 (en) Tank-binding kinase inhibitor compounds
AU2014348191A1 (en) Tetrahydroquinoline compositions as BET bromodomain inhibitors
WO2015027124A1 (en) Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
TW201100429A (en) N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
AU2009313198A1 (en) Compounds useful as inhibitors of ATR kinase
EP4313308A1 (en) Tead inhibitors and uses thereof
WO2026055409A1 (en) Pyrrolo-pyridazine inhibitors of jak2
HK40058075A (en) Intermediates and processes for the preparation of biaryl compounds
HK1229333B (en) Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
HK1229333A1 (en) Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
TW202545926A (zh) 作為菸鹼醯胺ｎ—甲基轉移酶抑制劑的哌啶衍生物
HK1236197A1 (en) Tank-binding kinase inhibitor compounds
HK1236197B (en) Tank-binding kinase inhibitor compounds

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: BIOGEN MA INC.

Free format text: FORMER NAME(S): BIOGEN MA INC.; SUNESIS PHARMACEUTICALS, INC.

FGA Letters patent sealed or granted (standard patent)